<SEC-DOCUMENT>0001558370-22-004113.txt : 20220323
<SEC-HEADER>0001558370-22-004113.hdr.sgml : 20220323
<ACCEPTANCE-DATETIME>20220323080836
ACCESSION NUMBER:		0001558370-22-004113
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220323
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220323
DATE AS OF CHANGE:		20220323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		22761629

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aytu-20220323x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/23/2022 11:44:51 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: d2102400-b4c9-4626-b3d5-00e4c827708a -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:aytu="http://www.aytubio.com/20220323" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityCentralIndexKey" id="Tc_grRMjbkbrkya0eGmTQZ7ng_1_1">0001385818</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:AmendmentFlag" id="Tc_jH1Nzdcw70qoCPmPVmHgwg_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="aytu-20220323.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_d0ddb65a_3065_4a95_9c54_c89a2f6cd6ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:DocumentType" id="Narr_AQTwDH-d3Eq5kRNZdSI0SQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-size:14pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported):</b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_bkSNmGZHy0Kme1W-EiBNNQ"><b style="font-weight:bold;"> March&#160;23, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityRegistrantName" id="Narr_qlQYwrSTREafoL1rpcNChA"><b style="font-weight:bold;">AYTU BIOPHARMA,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bc388308_3872_4b3b_a834_1bde8e559995"></a><a id="Tc_aV4BhAOmkUyD8bgFibAD7g_2_0"></a><a id="Tc_qTD-3Y0cs0K4bJbvEyzpvA_2_2"></a><a id="Tc_Dr05pTluGEqy9ma7irS4jQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:39.81%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:24.03%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:32.78%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:39.81%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_hxKDzkTEMU2KjHc3qwBZJw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:24.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityFileNumber" id="Tc_Ffra2ObuYEeoASMHUppBVQ_1_2"><b style="font-weight:bold;">001-38247</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:32.78%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityTaxIdentificationNumber" id="Tc_D7v459CsS0ywETII5aGkFQ_1_4"><b style="font-weight:bold;">47-0883144</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:39.81%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.03%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.78%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityAddressAddressLine1" id="Narr_kCTEBOCl1Ei50LcKFBDgJw"><b style="font-weight:bold;">373 Inverness Parkway</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityAddressAddressLine2" id="Narr_tNjdJBB6sEGDo5eLqG1NCw"><b style="font-weight:bold;">Suite&#160;206</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityAddressCityOrTown" id="Narr_SRzEhp7x-UOLn5xjcWOvFQ"><b style="font-weight:bold;">Englewood</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityAddressStateOrProvince" id="Narr_reZ8B5F6hEa2yKUs4xzxCg"><b style="font-weight:bold;">CO</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:EntityAddressPostalZipCode" id="Narr_3EMeWPzSkk2u2J2WpYZPhA"><b style="font-weight:bold;">80112</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:CityAreaCode" id="Narr_oynrW4SN1kmEQj3yJSlJRw"><b style="font-weight:bold;">720</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:LocalPhoneNumber" id="Narr_0ZY0jmqF2UOp4QhcYAHTvg"><b style="font-weight:bold;">437-6580</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="display:inline-block;width:18.25pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_oGncZR6xq0uTFqwTStyzxQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="display:inline-block;width:18.25pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_mNCf_BLHF068Vw-H2oMk4w"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="display:inline-block;width:18.25pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_pcLoUJotdkSzj9gvYXewjg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="display:inline-block;width:18.25pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_EUsqd0j37EGcajKqfBK2RA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_810a9833_6b78_460d_b0c4_ce6f37bb1d34"></a><a id="Tc_UpxzCiV2LUeppgXHqC9lTw_1_0"></a><a id="Tc_sLXrcocm20Sk5Pu8YwEGwA_1_2"></a><a id="Tc_Mt_Mp_qLj0qOMlAeOi3Itg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:17.78%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.5%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:40.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:40.38%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:Security12bTitle" id="Tc_z15GvvvpIkee70vJktkXWA_2_0"><b style="font-weight:bold;">Common Stock, par value $0.0001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.54%;background:#cceeff;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.78%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" name="dei:TradingSymbol" id="Tc_UKSmihzOtUObw0xWPac9AA_2_2"><b style="font-weight:bold;">AYTU</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.5%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_Q05n9yoNXkyY0H02zFxW1w_2_4"><b style="font-weight:bold;">The NASDAQ Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 10pt 7.2pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_hykzSstkbk-vA4DHqiblaw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_71582091_a394_45ed_8243_b6ab63e22011"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.01 Regulation FD Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 23, 2022, the Company issued a press release announcing that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT&#174; (methylphenidate) extended-release orally disintegrating tablet is now listed in the U.S. Food and Drug Administration (FDA) publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221;, commonly known as the &#8220;Orange Book&#8221;. A copy of the press release is attached as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b92dce48_329d_493b_a168_937bdb521121"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9.01 Financial Statements and Exhibits.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Exhibits.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.2%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:88.2%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.2%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1*</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.2%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aytu-20220323xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated March 23, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.2%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.2%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221;), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f6db38a4_5020_433f_9603_1ed5af3cb696"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:43.11%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:46.21%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:46.21%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:46.21%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 23, 2022</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;white-space:nowrap;width:43.11%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#160;Mark Oki</p></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43.11%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mark Oki</p></td></tr><tr><td style="vertical-align:top;width:53.78%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:43.11%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aytu-20220323xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/23/2022 11:45:09 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="aytu-20220323xex99d1001.jpg" alt="A picture containing text&#10;&#10;Description automatically generated" style="display:inline-block;height:56.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:138.73pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Cotempla XR-ODT</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ENGLEWOOD, CO / March 23, 2022 / </b><font style="font-size:11pt;">Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT&#174; (methylphenidate) extended-release orally disintegrating tablet is now listed in the U.S. Food and Drug Administration (FDA) publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221;, commonly known as the &#8220;Orange Book&#8221;. The Cotempla XR-ODT patent covers methods of use for the effective pediatric dosing of methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Cotempla XR-ODT is an orally disintegrating tablet containing methylphenidate and is indicated for the treatment of ADHD in patients 6 to 17 years old. FDA approved the New Drug Application for Cotempla XR-ODT in June 2017. The United States Patent and Trademark Office (USPTO)-issued US patent No. 11,166,947 entitled &#8220;Effective Dosing of a Child for the Treatment of ADHD with Methylphenidate&#8221; is now listed in the FDA&#8217;s Orange Book and carries a patent term to at least 2038. The listing of this patent extends the Orange Book patent exclusivity for Cotempla XR-ODT by over five years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#8220;We are pleased to expand and strengthen our intellectual property protection for Cotempla through the listing of this latest patent in the FDA&#8217;s Orange Book,&#8221; commented Josh Disbrow, chief executive officer of Aytu BioPharma. &#8220;Our prescription ADHD portfolio continues to grow given the growing need for ADHD medications and the unique clinical profile of both Cotempla XR-ODT and Adzenys XR-ODT as the only orally disintegrating tablets approved to treat ADHD. We are excited to protect this key commercial product through this new patent issuance and look forward to continuing to make Cotempla XR-ODT available for patients who need this important medication.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Patents listed in the Orange Book cover drugs that the FDA has approved and deemed both safe and effective for the general public&#8217;s use. Inclusion in the book&#8217;s list of patents can make it easier for drug makers to monitor for new generic drugs that could potentially arrive on the U.S. market and infringe on their patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About Cotempla XR-ODT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Cotempla XR-ODT is a central nervous system stimulant available in an extended-release orally disintegrating tablet formulation containing methylphenidate. Cotempla XR-ODT is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients 6 to 17 years of age. To view the full prescribing information as well as the BLACK BOX WARNING visit cotemplaxrodt.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IMPORTANT SAFETY INFORMATION FOR PATIENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Cotempla XR-ODT is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Cotempla XR-ODT in a safe place to protect it from theft. Selling or giving away your Cotempla XR-ODT may cause death or harm to others and is against the law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Who should not take Cotempla XR-ODT?</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Do not give Cotempla XR-ODT to your child if they are:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">allergic to methylphenidate or any ingredients in Cotempla XR-ODT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">taking or has taken an anti-depression medicine called monoamine oxidase inhibitor (MAOI) within the past 14 days.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">What is the most important information I should know about Cotempla XR-ODT?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Cotempla XR-ODT can cause serious side effects. Tell your healthcare provider about health conditions, including if your child:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">ever abused or been dependent on alcohol, prescription medicines, or street drugs. Cotempla XR-ODT has a high chance for abuse and can cause physical and psychological dependence.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">has any heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in people with heart problems or defects. Increased blood pressure and heart rate have been reported. Your healthcare provider should check for heart problems prior to prescribing Cotempla XR-ODT and will check your child&#8217;s blood pressure and heart rate regularly during treatment. Call the healthcare provider or go to the nearest hospital emergency room right away if your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">has mental problems, or a family history of suicide, bipolar illness, or depression. This is important because the following could occur: new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (hearing voices, or seeing or believing things that are not real) or new manic symptoms. Call your healthcare provider right away if there are any new or worsening mental symptoms or problems during treatment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">develops painful and prolonged erections (priapism). Priapism has happened in males who take products that contain methylphenidate. Get medical help right away if your child develops priapism.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">has circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud&#8217;s phenomenon). Fingers or toes may feel numb, cool, painful, and/or change color from pale, to blue, to red. Tell your healthcare provider if your child has numbness, pain, skin color change, or sensitivity to temperature in their fingers or toes. Call the healthcare provider right away if any signs of unexplained wounds appear on fingers or toes while taking Cotempla XR-ODT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">is having slowing of growth (height and weight). Your child should have his or her height and weight checked often while taking Cotempla XR-ODT. Treatment may be stopped if your child is not gaining weight or height.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">is pregnant or plans to become pregnant. It is not known if Cotempla XR-ODT will harm the unborn baby. If your child becomes pregnant during treatment with Cotempla XR-ODT, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">breastfeeding, or plans to breastfeed. You and your healthcare provider should decide if your child will take Cotempla XR-ODT or breastfeed.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">takes any medicines, including prescription and over-the-counter medicines (especially for depression, including MAOIs), vitamins, and herbal supplements. Cotempla XR-ODT and some medicines may interact with each other and cause serious side effects, or sometimes the dose of the other medicine will need to be adjusted.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Do not start any new medicine while taking Cotempla XR-ODT without talking to your healthcare provider first.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">What should I avoid during treatment with Cotempla XR-ODT?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">You should avoid drinking alcohol during treatment with Cotempla XR-ODT.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Common side effects of Cotempla XR-ODT include:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Decreased appetite, trouble sleeping, nausea, vomiting, indigestion, stomach pain, weight loss, anxiety, dizziness, irritability, mood swings, increased heart rate, and increased blood pressure.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">These are not all the possible side effects of Cotempla XR-ODT. Call your healthcare provider for medical advice about side effects.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">What</font> <font style="font-size:11pt;">is Cotempla XR-ODT?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Cotempla XR-ODT is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 to 17 years of age. COTEMPLA XR-ODT is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Keep Cotempla XR-ODT in a safe place to protect it from theft. Selling or giving away your Cotempla XR-ODT may cause death or harm to others and is against the law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About Aytu BioPharma, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company&#39;s prescription products include Adzenys XR-ODT&#174; (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT&#174; (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal&#174; ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor&#174; and Tri-Vi-Flor&#174;, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKC&#946; inhibitor in development for the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency. To learn more, please visit aytubio.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as &#39;&#39;may,&#39;&#39; &#39;&#39;will,&#39;&#39; &#39;&#39;should,&#39;&#39; &#39;&#39;forecast,&#39;&#39; &#39;&#39;could,&#39;&#39; &#39;&#39;expect,&#39;&#39; &#39;&#39;suggest,&#39;&#39; &#39;&#39;believe,&#39;&#39; &#39;&#39;estimate,&#39;&#39; &#39;&#39;continue,&#39;&#39; &#39;&#39;anticipate,&#39;&#39; &#39;&#39;intend,&#39;&#39; &#39;&#39;plan,&#39;&#39; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements, including but not limited to any statements regarding the intellectual property and product information presented in this press release. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the ability to protect our intellectual property, the future growth potential of our commercial portfolio, the anticipated start dates, durations and completion dates and the potential safety and efficacy of our product candidates. We also refer you to the risks described in &#39;&#39;Risk Factors&#39;&#39; in Aytu&#39;s Annual and Quarterly Reports on Form 10-K and 10-Q and in the other reports and documents it files with the Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Contact: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chelcie Lister</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">THRUST Strategic Communications</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">chelcie@thrustsc.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aytu-20220323xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20220323xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, +D# 2(  A$! Q$!_\0
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M73DJCY8:OR.KHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN\1W$,J%<1L>& /H?ZU]3UYQ\6_ <_B[2+>YTR%7U2T;"J2%\R,]5R?3K^=
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MJ_%GQNOV&\5=&L).)I=GE$KW'4L?IQ0,Y^XOK;4OVAH+FSE66$ZA&@=>A*@
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MRR*'NH_*1V=?+@"R$G/WGSDCG\:FBT.XLT46&H>26C2.;=$&W%1@,.>#CZT
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>aytu-20220323.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2022 11:44:55 AM-->
<!--Modified on: 3/23/2022 11:44:55 AM-->
<xsd:schema targetNamespace="http://www.aytubio.com/20220323" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:aytu="http://www.aytubio.com/20220323" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20220323_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20220323_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>aytu-20220323_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2022 11:44:55 AM-->
<!--Modified on: 3/23/2022 11:44:55 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>aytu-20220323_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/23/2022 11:44:55 AM-->
<!--Modified on: 3/23/2022 11:44:55 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="aytu-20220323.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637836326954379429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637836326954379429" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637836326954379429" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637836326954379429" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637836326954379429" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637836326954379429" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637836326954379429" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637836326954379429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637836326954379429" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637836326954389434" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637836326954389434" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637836326954389434" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637836326954389434" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637836326954389434" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_637836326954389434" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_637836326954389434" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637836326954389434" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637836326954389434" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637836326954389434" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637836326954389434" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637836326954389434" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637836326954389434" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637836326954399415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637836326954399415" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637836326954399415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637836326954399415" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637836326954399415" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637836326954399415" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140043142389128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 23,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOPHARMA,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0883144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">373 Inverness Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite&#160;206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Englewood<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">437-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>aytu-20220323x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aytu-20220323.xsd" xlink:type="simple"/>
    <context id="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_grRMjbkbrkya0eGmTQZ7ng_1_1">0001385818</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_jH1Nzdcw70qoCPmPVmHgwg_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_AQTwDH-d3Eq5kRNZdSI0SQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_bkSNmGZHy0Kme1W-EiBNNQ">2022-03-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_qlQYwrSTREafoL1rpcNChA">AYTU BIOPHARMA,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_hxKDzkTEMU2KjHc3qwBZJw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_Ffra2ObuYEeoASMHUppBVQ_1_2">001-38247</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_D7v459CsS0ywETII5aGkFQ_1_4">47-0883144</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_kCTEBOCl1Ei50LcKFBDgJw">373 Inverness Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_tNjdJBB6sEGDo5eLqG1NCw">Suite&#160;206</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_SRzEhp7x-UOLn5xjcWOvFQ">Englewood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_reZ8B5F6hEa2yKUs4xzxCg">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_3EMeWPzSkk2u2J2WpYZPhA">80112</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_oynrW4SN1kmEQj3yJSlJRw">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_0ZY0jmqF2UOp4QhcYAHTvg">437-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_oGncZR6xq0uTFqwTStyzxQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_mNCf_BLHF068Vw-H2oMk4w">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_pcLoUJotdkSzj9gvYXewjg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_EUsqd0j37EGcajKqfBK2RA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_z15GvvvpIkee70vJktkXWA_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_UKSmihzOtUObw0xWPac9AA_2_2">AYTU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Tc_Q05n9yoNXkyY0H02zFxW1w_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg"
      id="Narr_hykzSstkbk-vA4DHqiblaw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ $4%W5&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( !%!=U2SI >.[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !%!=U297)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ $4%W5']"[LY:!   $A$  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !%!=U2?H!OPL0(
M .(,   -              "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aytu-20220323x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aytu-20220323x8k.htm">aytu-20220323x8k.htm</File>
    <File>aytu-20220323.xsd</File>
    <File>aytu-20220323_lab.xml</File>
    <File>aytu-20220323_pre.xml</File>
    <File>aytu-20220323xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aytu-20220323x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "aytu-20220323x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aytu-20220323_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aytu-20220323_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aytu-20220323.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "aytu",
   "nsuri": "http://www.aytubio.com/20220323",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aytu-20220323x8k.htm",
      "contextRef": "Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aytu-20220323x8k.htm",
      "contextRef": "Duration_3_23_2022_To_3_23_2022_MtRUKBf7102xocmB8Rhexg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-22-004113-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-004113-xbrl.zip
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M+6\%6&,_BOU![:*D]O6VH.K8J88ZW(!0BJS+RR$=3I(N&D';6*JP+T- Z^P
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M=X8^RHBW3O&J?_5/_ZPSZK1D!F@;6QYY &-R'L' 1H2"QB;>T2&3XKS'I0Z
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M%D<L9UZ6YA@3^*?K]ZVC_P=02P,$%     @ $4%W5%>N!!DT%0  #FX  !@
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MZ'2.@OX=%#!SOEM$8>"KU0("2*'[G1>';D'ALSB4\-RP/%F!#&TT)KQ"XI%
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M_5\ZXS^=]NI_4$L! A0#%     @ $4%W5+V>PMMG P  _ L  !$
M     ( !     &%Y='4M,C R,C S,C,N>'-D4$L! A0#%     @ $4%W5$+L
MXEF+!0  CCX  !4              ( !E@,  &%Y='4M,C R,C S,C-?;&%B
M+GAM;%!+ 0(4 Q0    ( !%!=U2^CQ?=B00  (DG   5              "
M 50)  !A>71U+3(P,C(P,S(S7W!R92YX;6Q02P$"% ,4    "  107=4$""+
M]?<4  !RDP  %               @ $0#@  87ET=2TR,#(R,#,R,W@X:RYH
M=&U02P$"% ,4    "  107=45ZX$&305   .;@  &               @ $Y
M(P  87ET=2TR,#(R,#,R,WAE>#DY9#$N:'1M4$L%!@     %  4 30$  *,X
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
